Dr. Oleg Krijanovski is an internist in Ann Arbor, Michigan and is affiliated with Alta Bates Summit Medical Center. He received his medical degree from Russian State Medical University and has been in practice for 29 years.
Education & Medical Training
University of Michigan Hospitals and Health Centers
Residency, Anatomic and Clinical Pathology, 1999–2001
University of Michigan Hospitals and Health Centers
Residency, Internal Medicine, 2001–2003
University of Michigan Hospitals and Health Centers
Fellowship, Hematology/Oncology, 2003–2006
Russian State Medical University
Class of 1985
Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
KrijanO@sutterhealth.org
Related Clinical Trials
Bone Marrow Transplant Database
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Investigators: Deepti Behl MD, Oleg I. Krijanovski M.D., Ph.D.
Status: Active, Recruiting
Commands
ACE-536 VS.Epoetin Alfa for the TX of Anemia Due to IPSS-R Very Low,Low or Intermediate Risk MDS in ESA Naïve Subjects Who Require RBC Transfusions
Investigators: Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Connect
Connect® MDS/AML Disease Registry
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Myelofibrosis (INCB 50465-304)
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Myelofibrosis (INCB 50465-313)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibros
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting